Expert Review of Anticancer Therapy最新文献_第6页

The burden of acute myeloid leukemia: an integrated review of clinical, economic, and patient-centered evidence. 急性髓性白血病的负担：临床、经济和以患者为中心的证据的综合回顾。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-08-06 DOI: 10.1080/14737140.2026.2705531

Amer M Zeidan, Ruizhi Zhao, Dina Christensen, Janan Amin, Thomas W LeBlanc

{"title":"The burden of acute myeloid leukemia: an integrated review of clinical, economic, and patient-centered evidence.","authors":"Amer M Zeidan, Ruizhi Zhao, Dina Christensen, Janan Amin, Thomas W LeBlanc","doi":"10.1080/14737140.2026.2705531","DOIUrl":"10.1080/14737140.2026.2705531","url":null,"abstract":"Introduction: Acute myeloid leukemia (AML) is an aggressive hematologic cancer that accounts for approximately one third of all newly diagnosed leukemias annually in the United States (US), and is associated with high mortality and substantial clinical, economic and patient burden.Areas covered: Prior reviews have explored AML disease burden from isolated epidemiological, treatment, or cost perspectives. In this narrative review, we integrate the published evidence identified through targeted searches of PubMed and Google Scholar conducted between June 2025 and July 2026. Literature published between 2006 and 2026 addressing the epidemiologic, clinical, economic and humanistic burden of AML was reviewed to characterize unmet needs across the continuum of care, from diagnosis and treatment selection to patient outcomes including remission, relapse, and death.Expert opinion: Significant unmet needs persist across all burden dimensions, particularly for older patients and those ineligible for intensive chemotherapy. Therefore, expanded access to targeted therapies, oral regimens, and supportive care models has the potential to enhance health-related quality of life and reduce 'time toxicity/burden' for patients. The multifaceted aspects of AML burden necessitate a treatment approach that balances safety and efficacy with patient preference and patient-centered value, to optimize outcomes for patients, caregivers, and healthcare systems.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-15"},"PeriodicalIF":3.0,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148469779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The clinical utility of molecular residual disease testing in early-stage breast cancer. 早期乳腺癌分子残留病检测的临床应用

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-08-01 Epub Date: 2026-02-13 DOI: 10.1080/14737140.2026.2630023

John P Micha, Randy Bohart, Bram H Goldstein

{"title":"The clinical utility of molecular residual disease testing in early-stage breast cancer.","authors":"John P Micha, Randy Bohart, Bram H Goldstein","doi":"10.1080/14737140.2026.2630023","DOIUrl":"10.1080/14737140.2026.2630023","url":null,"abstract":"Introduction: Breast cancer is the most commonly-diagnosed malignancy among women. Currently, radiologic imaging is indicated for defined surveillance periods and to assess or corroborate patient symptomatology. More recently, the advent of circulating tumor DNA (ctDNA) assays has conferred a potential enhancement in disease monitoring via the evaluation of molecular residual disease (MRD).Areas covered: Studies have shown that MRD testing reportedly eventuates in a lead-time predictive benefit in diagnosing progressive disease compared to traditional assessment. In particular, the Signatera test has compelling advantages compared to many of the available MRD tests, especially given the reported clinical data with MRD testing in early-stage breast cancer. In the current review, we recount the results from several studies on the topic of MRD testing in the treatment and surveillance of breast cancer.Expert opinion: MRD testing in early-stage breast cancer theoretically confers a significant clinical benefit with adjuvant therapy and during patient surveillance. However, there are concerns with the potential for aggressive or prolonged treatment, not to mention the specific approach to managing patients who are ctDNA positive but remain asymptomatic.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"991-994"},"PeriodicalIF":3.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146156379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune checkpoint inhibitors in urothelial carcinoma: a practical framework for patient selection, toxicity management, response assessment, and treatment sequencing. 尿路上皮癌免疫检查点抑制剂：患者选择、毒性管理、反应评估和治疗排序的实用框架。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-08-01 Epub Date: 2026-02-10 DOI: 10.1080/14737140.2026.2628071

Abdul Rahman Al Armashi, Jenny Gong, Pedro Barata, Jason Brown, Jorge Garcia, Iris Sheng

{"title":"Immune checkpoint inhibitors in urothelial carcinoma: a practical framework for patient selection, toxicity management, response assessment, and treatment sequencing.","authors":"Abdul Rahman Al Armashi, Jenny Gong, Pedro Barata, Jason Brown, Jorge Garcia, Iris Sheng","doi":"10.1080/14737140.2026.2628071","DOIUrl":"10.1080/14737140.2026.2628071","url":null,"abstract":"Introduction: Managing urothelial carcinoma with immune checkpoint inhibitors requires addressing issues beyond clinical outcomes. Implementation difficulties affect most patients, predictive biomarkers show limited utility, and treatment discontinuation from toxicity remains problematic.Areas covered: This article integrates clinical trials, systematic reviews, health-system evaluations, and guidelines from 2016 to 2025. We detail limitations of programmed death-ligand 1 (PD-L1) expression, panel-based tumor mutational burden (TMB), clinic-ready toxicity pathways, immune-appropriate response criteria (iRECIST), pseudoprogression, hyperprogression, post-ICI sequencing (FGFR3 alterations, enfortumab vedotin-based therapy, chemotherapy, trials), and delivery models (navigation, electronic patient-reported outcomes, telemedicine, payment structures).Expert opinion: Optimizing systemic frameworks for immunotherapy care requires careful evaluation of functional status, protocols for immune-related adverse events management, standardization for assessments of clinical responses, and ensuring equitable access to care. ctDNA and AI-assisted radiomics are promising adjuncts to clinical care, but still require multi-center prospective validation before adoption into routine practice.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1003-1017"},"PeriodicalIF":3.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146141654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The pricing barrier: cost-effectiveness of Glofitamab for relapsed/refractory DLBCL in China beyond threshold and value-based pricing strategy considerations. 定价障碍：格非他抗治疗复发/难治性DLBCL在中国的成本效益超过阈值和基于价值的定价策略考虑。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-08-01 Epub Date: 2026-02-25 DOI: 10.1080/14737140.2026.2630025

Shen Lin, Xiangzhen Wang, Lijing Yang, Shaohong Luo, Xiaoting Huang, Xiuhua Weng, Xiongwei Xu

{"title":"The pricing barrier: cost-effectiveness of Glofitamab for relapsed/refractory DLBCL in China beyond threshold and value-based pricing strategy considerations.","authors":"Shen Lin, Xiangzhen Wang, Lijing Yang, Shaohong Luo, Xiaoting Huang, Xiuhua Weng, Xiongwei Xu","doi":"10.1080/14737140.2026.2630025","DOIUrl":"10.1080/14737140.2026.2630025","url":null,"abstract":"Background: To assess the cost-effectiveness of Glofitamab plus Gemcitabine and Oxaliplatin (Glofit-GemOx) versus Rituximab plus Gemcitabine and Oxaliplatin for treating relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) in China.Research design and methods: A partitioned survival model utilized data from the phase 3 STARGLO trial, extrapolating progression-free survival and overall survival via parametric distributions. Costs and utilities were derived from Chinese databases and literature, covering drug expenses, adverse event management, and subsequent therapies. Incremental cost-effectiveness ratios (ICERs) were assessed against a willingness-to-pay (WTP) threshold of $40,343 per quality-adjusted life year (QALY). Sensitivity and budgetary impact analyses were conducted.Results: Glofit-GemOx yielded an additional 1.47 QALYs (2.64 vs. 1.17) at an incremental cost of $92,765, resulting in an ICER of $63,379/QALY, exceeding the WTP threshold. Key drivers included Glofitamab's price and utility parameters. Probabilistic sensitivity analysis showed a 14.5% probability of cost-effectiveness at the threshold. A 30% price reduction would be required to achieve cost-effectiveness. The five-year budget impact analysis projected sustained and substantial incremental costs associated with Glofit-GemOx.Conclusions: Although Glofit-GemOx offers significant survival benefits, it is not cost-effective in China at current prices. Price reductions or insurance coverage could improve accessibility, supporting the need for value-based pricing strategies.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1071-1078"},"PeriodicalIF":3.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147283130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of PSMA PET/CT imaging in identifying low-risk prostate cancer candidates for active surveillance after biopsy. PSMA PET/CT成像在活检后主动监测低风险前列腺癌候选人中的作用

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-08-01 Epub Date: 2026-03-05 DOI: 10.1080/14737140.2026.2640232

Levent Kabasakal, Gürsan Kaya

引用次数: 0

ESMO 2025 and new therapies in breast cancer: does society always benefit? ESMO 2025和乳腺癌新疗法：社会总能受益吗？

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-08-01 Epub Date: 2026-03-26 DOI: 10.1080/14737140.2026.2649949

Nabil Ismaili

引用次数: 0

Clinical management of oligoprogressive renal cell carcinoma. 少进展性肾细胞癌的临床治疗。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-08-01 Epub Date: 2026-04-14 DOI: 10.1080/14737140.2026.2657923

Ezra A Bernstein, Jonathan Schoenhals, Shawn Dason, Shang-Jui Wang, Eric A Singer, Karie Runcie

{"title":"Clinical management of oligoprogressive renal cell carcinoma.","authors":"Ezra A Bernstein, Jonathan Schoenhals, Shawn Dason, Shang-Jui Wang, Eric A Singer, Karie Runcie","doi":"10.1080/14737140.2026.2657923","DOIUrl":"10.1080/14737140.2026.2657923","url":null,"abstract":"Introduction: Nearly 81,000 new cases of renal cell carcinoma are expected to be diagnosed in 2025, with more than one-third of patients presenting with or eventually developing metastatic disease. Some patients develop oligoprogressive disease, defined by limited metastatic progression.Areas covered: We discuss current data evaluating the treatment approaches to patients with oligoprogressive disease. This includes active surveillance, systemic therapy, and metastasis-directed therapy such as surgical resection, stereotactic ablative radiotherapy, and percutaneous thermal ablation. We also describe the disease characteristics that we consider when deciding on the appropriate therapy for patients with oligoprogressive disease. We searched databases such as PubMed and ClinicalTrials.gov from 2000 to 2026 for trials related to these treatment options.Expert opinion: Patients with oligoprogressive RCC with favorable or intermediate-risk disease and limited metastases may benefit from metastasis-directed therapy. Patients that progress on immunotherapy and require subsequent therapy should consider a tyrosine kinase inhibitor. Biomarkers are being explored to better risk-stratify patients for metastasis directed therapy.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1041-1049"},"PeriodicalIF":3.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147671856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiotheranostics in solid tumors: focus on radiopharmaceutical therapy and clinical challenges. 实体肿瘤的放射治疗：关注放射药物治疗和临床挑战。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-08-01 Epub Date: 2026-03-27 DOI: 10.1080/14737140.2026.2649220

Daniela Lucente, Stefania Bellino, Anna La Salvia

{"title":"Radiotheranostics in solid tumors: focus on radiopharmaceutical therapy and clinical challenges.","authors":"Daniela Lucente, Stefania Bellino, Anna La Salvia","doi":"10.1080/14737140.2026.2649220","DOIUrl":"10.1080/14737140.2026.2649220","url":null,"abstract":"Introduction: Theranostic radiopharmaceuticals represent a significant advancement in personalized medicine, particularly in oncology. By integrating diagnostic imaging and targeted radionuclide therapy within a single molecular platform, these agents enable selective delivery of cytotoxic radiation to tumor cells. This integrated 'diagnose-then-treat' paradigm enables precise patient selection, individualized treatment planning, and response assessment.Areas covered: A comprehensive literature search was performed using major biomedical databases, including PubMed, Scopus, and Web of Science. Clinical successes such as peptide receptor radionuclide therapy for neuroendocrine tumors (NETs), and Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) for metastatic castration-resistant prostate cancer underline the promise of radiotheranostics. Rapid innovation is driving personalized dosimetry from research into clinical practice, improving the balance between efficacy and toxicity. Furthermore, improved target selection using PET imaging is becoming essential for optimal patient selection and clinical trial design.Expert opinion: Despite these advances, critical challenges persist, including toxicity management and heterogeneous target expression; additionally, radionuclide production, supply logistics, and cold-chain requirements remain significant barriers to widespread adoption; finally, standardization issues, harmonized imaging protocols, and clear response criteria further complicate patient selection. The field's advancement will rely on robust randomized clinical trials and innovative combination strategies to address tumor heterogeneity and resistance.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"995-1001"},"PeriodicalIF":3.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147480328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mirdametinib in symptomatic neurofibromatosis type 1 plexiform neurofibromas. 米达替尼治疗症状性神经纤维瘤病1型丛状神经纤维瘤。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-08-01 Epub Date: 2026-03-16 DOI: 10.1080/14737140.2026.2645395

Kester A Phillips, David Schiff

{"title":"Mirdametinib in symptomatic neurofibromatosis type 1 plexiform neurofibromas.","authors":"Kester A Phillips, David Schiff","doi":"10.1080/14737140.2026.2645395","DOIUrl":"10.1080/14737140.2026.2645395","url":null,"abstract":"Introduction: Neurofibromatosis type 1 (NF1) is a rare genetic disorder frequently complicated by plexiform neurofibromas (PNs) - benign but often morbid tumors associated with pain, disfigurement, and functional impairment. Mitogen-activated protein kinase (MEK) inhibitors have emerged as an approach for the management of NF1-PNs.Areas covered: This review summarizes the pharmacology, mechanism of action, preclinical rationale, and clinical development of mirdametinib, a selective MEK1/2 inhibitor approved for the treatment of symptomatic, inoperable NF1-PNs in children and adults. We review key pharmacokinetic and pharmacodynamic properties, preclinical data supporting MAPK/ERK pathway inhibition, and outcomes from mirdametinib clinical trials. Emphasis is placed on efficacy outcomes, patient-reported benefits, durability of response, safety profile, and regulatory milestones. Emerging evidence from indirect treatment comparisons and early combination strategies is also discussed to contextualize mirdametinib within the evolving therapeutic landscape.Expert opinion: Mirdametinib represents a meaningful advance in the management of NF1-PNs, offering durable tumor volume reduction, improvements in pain and quality of life, and a manageable safety profile across age groups. While head-to-head comparisons with other MEK inhibitors are lacking, available evidence suggests a favorable balance of efficacy and tolerability that may support its use as a first-line systemic option in appropriately selected patients.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"977-985"},"PeriodicalIF":3.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147431643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The evolving survival landscape in advanced non-small cell lung cancer: an interrupted time series analysis. 晚期非小细胞肺癌不断变化的生存环境：中断时间序列分析。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-08-01 Epub Date: 2026-02-11 DOI: 10.1080/14737140.2026.2628946

Jianwei Ji, Taoying Li, Zhanwu Li, Jianhua Zhou, Fuhong Qin, Mengmeng Teng

{"title":"The evolving survival landscape in advanced non-small cell lung cancer: an interrupted time series analysis.","authors":"Jianwei Ji, Taoying Li, Zhanwu Li, Jianhua Zhou, Fuhong Qin, Mengmeng Teng","doi":"10.1080/14737140.2026.2628946","DOIUrl":"10.1080/14737140.2026.2628946","url":null,"abstract":"Background: Treatment of advanced non-small cell lung cancer (NSCLC) has shifted from chemotherapy to targeted therapy and immunotherapy. We aimed to evaluate the effects of these novel therapies on advanced NSCLC in real-world setting.Research design and methods: We conducted a retrospective cohort study using the SEER database of patients with advanced NSCLC receiving systemic therapy. Patients were stratified into three periods: chemotherapy (1992-2002), targeted therapy (2003-2014), and immunotherapy (2015-2022). We used interrupted time series analysis to evaluate changes in overall survival rate and cancer-specific survival rate (CSSR).Results: The analysis included 32,899 patients. Compared to chemotherapy (11.9 months), median overall survival was significantly longer with targeted therapy (19.3 months) and immunotherapy (27.4 months). The 3-year CSSR increased by 0.36% and 0.89% per year following targeted therapy and immunotherapy, respectively. Adenocarcinoma showed sustained improvement in 3-year CSSR after targeted therapy (0.52% per year) and immunotherapy (0.83% per year), while squamous cell carcinoma showed no significant change. Most subgroups showed continuous survival improvement after immunotherapy.Conclusion: The introduction of targeted therapy and immunotherapy has produced significant survival improvement in adenocarcinoma, with the most pronounced benefits with immunotherapy. Treatment efficacy varies across subgroups highlighting the need for further investigation to optimize personalized therapy.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1051-1060"},"PeriodicalIF":3.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146124009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0